Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 18Lymphoma, Large B-Cell, Diffuse 9Lymphoma, B-Cell 7Lymphoma, Non-Hodgkin 6Lymphoma 5Sarcoma 3Rhabdoid Tumor 3Recurrence 3Lymphoma, Mantle-Cell 3Wilms Tumor 2Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Mesothelioma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Lymphoma, T-Cell, Cutaneous 1Leukemia 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Peripheral Blood Stem Cell Transplantation 25Whole-Body Irradiation 18Etoposide 18Doxorubicin 17Vincristine 16Mycophenolic Acid 16Cyclosporine 16Prednisone 15Tacrolimus 12Busulfan 12Bortezomib 12Methotrexate 11Antilymphocyte Serum 11Rituximab 10Melphalan 10Gemcitabine 9Carboplatin 9Lenalidomide 8Filgrastim 8Vorinostat 7Radiotherapy 7Everolimus 7Therapeutics 6Flow Cytometry 6Alemtuzumab 6romidepsin 5Methylprednisolone 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × tazemetostat × Lymphoid × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡